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    INTRODUCTION 
Idiopathic non-cirrhotic intra-hepatic portal hypertension (NCIPH)1 2 3 
is a term that defines one or more entities characterized by intra-hepatic 
portal hypertension and good to excellent liver function.(See references 
inserted on the previous page)  This definition encompasses a number of 
entities including non-cirrhotic portal fibrosis (NCPF) and idiopathic portal 
hypertension (IPH) and is sometimes difficult to differentiate from well 
compensated cirrhosis.  By definition this excludes causes like  extra-hepatic 
portal vein obstruction and Budd Chiari Syndrome. 
 The etio-pathogenesis of NCIPH is poorly understood with a number 
of hypotheses proposed in the past. Arsenic toxicosis from contaminated 
drinking water is a possible etiological factor for NCIPH in India6 .Infective 
hypothesis was put forward with the possibility of umbilical sepsis, bacterial 
infection and diarrhoeal episodes in infancy and early childhood leading to 
portal pyemia, pylephlebitis resulting in thrombosis, sclerosis and 
obstruction of small and medium sized portal vein radicals 7. 
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The role of  prothrombotic disorders in causing obstructive portal 
venopathy has been investigated.  One study from the West showed the 
prevalence of identified prothrombotic disorders in the study cohort was 
higher (54%) when compared to that expected in the general western 
population (8-15%)8. A deranged immune response and reduced cell 
mediated immunity was seen in patients with NCPF in a study published 
from India9 . 
In this present study we aimed to evaluate the folate metabolism with 
special reference to methylene tetrahydrofolate reductase(MTHFR) gene 
mutations in patients with NCIPH.  Vitamin B12 and folate are essential 
cofactors in homocysteine metabolism and deficiency of these vitamins are 
associated with hyperhomocysteinemia.26 which is associated with increased 
risk of arterial and venous thrombosis 27.  A recent study from Turkey which 
looked at thrombophilic mutation profile in NCIPH showed significantly 
higher incidence of MTHFR gene mutations in patients than controls 28 . The 
aim of the present study was to evaluate the serum levels of folate, vitamin 
B12 and homocysteine and to evaluate methylene tetrahydrofolate reductase 
(MTHFR) gene mutations in patients with NCIPH spectrum disease and to 
compare them with cirrhosis of known cause and matched healthy controls. 
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AIMS & OBJECTIVES 
The hypothesis is that non-cirrhotic intrahepatic portal hypertension 
(NCIPH) occurs secondary to a defect in folate metabolism, that leads to a 
procoagulant status and vascular occlusion. 
The aims of the present study were to evaluate the serum levels of 
folate, vitamin B12  and homocysteine and to evaluate methylene 
tetrahydrofolate reductase (MTHFR) gene mutations in patients with NCIPH 
spectrum disease and to compare them with cirrhosis of known cause and 
matched healthy controls. 
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REVIEW OF LITERATURE 
Historical background: 
During 1984 to 1910, Banti In Italy proposed the disorder morbus 
Banti, which is characterized by primary cryptogenic splenomegaly and 
anemia not associated with any known hematologic disease10.   
In 1954, Tisdale et al  described four patients with portal hypertension 
and massive bleeding from esophageal varices in whom no intra hepatic nor 
extra hepatic  portal obstruction was found11.  
Later Ramalingaswami et al in India (in 1962) noticed a similar 
disease while studying autopsy materials and characterized the histological 
lesion as obliterative portal venopathy 12. In 1969, the title “non-cirrhotic 
portal fibrosis’ was officially adopted at a workshop organized by the Indian 
Council of Medical Research.  
Mikkelsen et al in Los angeles described 35 patients with 
splenomegaly and non-cirrhotic portal hypertension in whom phlebosclerotic 
processes were apparent in the intra and extra hepatic portal vein system and 
called the disease as “ hepato portal sclerosis” 13 
With similar publications coming from various countries it is 
established that this entity called with different names does exist throughout 
the world, being more common in developing  countries.  The various names 
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that are synonymously used are Hepatoportal sclerosis, NCPF, Obliterative 
portal venopathy, Non cirrhotic intra hepatic portal hypertension and 
Idiopathic presinusoidal portal hypertension.  
Epidemiology: 
NCIPH has been reported to be common in socioeconomically 
disadvantaged in India.  
In 1985, the reported incidence of IPH in Japan was 
0.75/105population and in 1992 only an average of 11 new patients were 
reported showing a declining incidence (related to improved hygiene and 
standards of living)14.  The incidence of IPH has not been prospectively 
studied in India. Most of the services from difference part of India show a 
male predominance of 2: 1 to 4:112,15,16. 
In Japan, IPH was more common in older females with a female to 
male ratio of 3:1 and an average age of 40.6 years12. 
In a study from North India it was reported that NCPF is on decline in 
India18. But a recent study from our centre documented NCIPH as a common 
cause of cryptogenic intra hepatic portal hypertension (to be published). 
Etiology: 
Etiopathogenesis of NCIPH is poorly understood and a number of 
hypotheses have been proposed.  
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Infective hypothesis: 
Abdominal infection at birth or in early childhood has been alleged to 
play an important role19.  Umbilical sepsis, bacterial infections and diarrheal 
episodes in infancy and in early childhood are likely to lead to portal 
pyemia, pylephlebitis, resulting in thrombosis,sclerosis and obstruction of 
small and medium sized portal vein radicals29. 
Exposure to Chemicals: 
Prolonged ingestion of arsenic has been related to causation of 
NCPF20.  Histological picture that resembles NCPF has been observed 
following chronic exposure to vinyl chloride monomers, copper suflate 
(vineyard sprayers), protracted treatment with methotrexate, 
hypervitaminosis A and in recipients of renal allografts who received 
treatment with 6-mercaptopurine, azathioprine 21.  
Immunological and immunogenetic hypotheses: 
Evidence supporting these hypotheses includes: a reduction in the 
suppressor/cytotoxic T lymphocytes (T8) in NCPF patients  
i. a decreased T4/T8 lymphocytic ratio  
ii. a reduction in the cell-mediated immune status in NCPF patients  
iii. poor autologous mixed lymphocyte reaction (MLR)22 
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No definite genetic predisposition to NCPF has been reported. 
Prothrombotic disorder:   
In a retrospective study of 28 NCIPH patients, prothrombotic 
disorders were detected in 12 (48%) patients8.  The  disorders found were 
myeloproliferative disorder, protein C and S deficiency and  APL syndrome.  
There were  two case reports  of NRH(Nodular regenerative 
hyperplasia) associated with IgA aCL and evidence of poorly compliant 
coeliac disease54. There was a suggestion that  T cell help from gluten 
specific T cells is responsible for driving the IgA  autoantibody response to 
both transglutaminase and protein/phospholipid  complexes, leading to the 
formation of IgA aCL. IgA aCL then trigger  thrombosis in small portal vein 
radicles, which drain the inflamed small  intestine. 
Hyperhomocysteinemia – Prothrombotic state 
Homocysteine is a naturally occurring molecule in the body and it is 
required in several reaction within the cells resulting in the formation of 
cysteine and methionine, which can be in the further used by the body.  If 
the pathways   to either cysteine or methionine  are blocked, then 
homocysteine levels may use.Methionine synthase requires vitamin B12 
(methylcobalamin) in order to carry out its reaction.  If a patient does not 
have an adequate supply of vitamin B12, then homocysteine is not converted  
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to methionine and the net result is an increase in homocysteine.  MTHFR is 
required to form 5-methyltetrahydrofolate which is required to convert 
homocysteine to methionine.  If this cannot be formed, then homocysteine 
levels will increase. Cystathionine betasynthase is required to convert 
Homocysteine to methionine and its deficiency also leads to increased 
homocysteine. 
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BACKGROUND ON FOLATE AND B12 METABOLISM 
Folic acid is a carrier of one-carbon fragments which it transfers to 
various biochemical targets.  The one-carbon piece can be in several 
different oridation states but two important forms of folic acid are 
methyltetrahydrofolate and methyelene –THF 
 
Three factors involved in the methionine cycle could influence plasma 
homocysteine concentrations:  MTHFR polymorphism, vitamin B12- an 
essential cofactor and folate- the substrate.   
Methyelene tetrahydrofolate reductase 677 (MTHFR 677) 
polymorphism  ay provide hyperhomoysteinemia when folate status is low.  
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In a study published from Germany23 it was found that MTHFR 677 TT 
individuals are more liable to hyperhomocysteinemia under vitamin B12 
deficiency than the other two genotypes.  In such a case, relative folate 
shortage may progressively increase homocysteine levels.  TT individual 
may have increased folate and vitamin B12, requirements compared to the 
other CC and CT genotypes23. 
An Elevated Homocysteine level 
“Normal” and “abnormal” values are set by individual laboratory.  
Typically, a level less than 13 micr mol/L is considered normal. A level 
between 13 and 60 u mol/L is considered moderately elevated.  A  value 
greater than 60-100 u mol/L is severely elevated24  
Risks associated with Elevated homocysteine levels25: 
o Coronary artery disease (atherosclerosis) 
o Heart attack 
o Stroke 
o Peripheral arterial disease 
o Venous thrombosis – Deep vein thrombosis, Pulmonary embolism 
o Dementia 
o Having a child with a neural tube defect. 
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The 5,10 MTHFR gene is located on chromosome at 1 at 1p36.3. The 
complementary DNA sequence is 2.2 Kilobases long and consists of 11 
exons30. 
 
The major product of the MTHFR gene is a catalytically active 77 
Kilodalton protein . 
5,10-methylene tetrhydrofolate reductase (MTHFR) converts 5,10 
methylene THF into 5-methyl THF, a major circulating form of folate. 
5 methyl THF provides methyl group for homocysteine methylation31. Two 
common polymorphism in the MTHFR gene, a C to T transition at 
nucleotide 677 (C677T) ,an A to C transition at portion 1298 (A1298C) are 
associated with a 50-60% decrease in catalytic activity33. 
The T677 variation causing alanine to valine substitution at the codon 
222 affects the catalyte MTHFR domain leading toa thermolabile enzyme 
with reduced catalytic activity.  Homozygosity for valine 222 predisposes to 
the development of hyperhomocysteinemia, especially during times of folate  
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insufficiency. 
A C 1298 variation causing the replacement of glumate by alanine at 
the codon position 429 affects regulatory MTHFR domain.  Homozygosity 
for alanine 429 is associated with lower enzymatic activity but does not 
seem to influence homocysteine plasma levels, except when accompanied by 
T677 mutation33. 
C677 T allele: This is characterized by a point mutation at position 
677 of the MTHFR gene that converts a cytosine C into a thymineT. This 
mutation results in a amino acid substitution (alanine to valine) in the 
enzyme.  The C677T allele is commonly called “thermolabile”, because the 
activity of the encoded enzyme is reduced at 370 C or more.   
A1298 allele (A1289 C) – In the A1298 C allele, a point mutation in 
exon 7 results in an amino acid substitution (glutamate for alanine) in the 
enzyme.  This allele has also been called the C1289 A allele.  The activity of 
the encoded enzyme is decreased, although less than is the case with the 
C677T allele.  People who are homozygous for the A1298C allele do not 
appear to have high serum homocysteine levels than controls.  However, 
people who are compared heterozygous for the A1298C and C677T alleles 
tend to have a biochemical profile similar to that seen among C677T 
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homozygotes, with increased serum homocysteine levels and decreased 
serum folate levels33.  
Population Frequencies: 
In a study from South India. homozygous MTHFR A1298C SNP was 
detected in 15.3% of the individuals tested and 47.2% were heterozygous for  
this SNP. 
Homozygosity for the C677T SNP (single nucleotide polymorphism) 
was detected in 1.38% and the frequency of the C677T heterozygotes was 
18.1%.  The frequency of double heterozygosity was 19.6% and the 
frequency of double homozygosity was completely absent34.  
MTHFR and Liver Disease 
In an Italian study 35 ,MTHFR C677T mutations were looked at  in 
patients with liver cirrhosis (LC) and with or without portal vein thrombosis 
(PVT). Multivariate analysis of seven variables showed a statistically 
significant relationship between MTHFR C677T homozygous state and 
cryptogenic liver cirrhosis( P value of 0.004  ; Odds ratio of  6.87; 95% CI  
1.43–25.55),age ,alcohol abuse and presence of  PVT. The conclusion was 
that MTHFR C677T-related endothelial damage can result in both PVT and 
vascular damage, ischemic injury and fibrosis, prompting cirrhosis  
development from any etiology. 
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In a study from Turkey which analysed thrombophilic mutations and 
natural anticoagulant deficiency in patients with Idiopathic portal 
hypertension, MTHRF C677T and MTHFR A1298C frequencies of genetic 
polymorphisms were found to be significantly higher among patients than 
that of controls36.  
Clinical presentation of NCIPH: 
These patients present with well tolerated episodes of gastrointestinal 
haemorrhage, a long standing mass in the left upper quadrant 
(splenomegaly), anemia and consequences of hypersplenism. 
  Development  of ascites, jaundice and hepatic encephalopathy is 
uncommon and may be  seen only after an episode of  gastrointestinal  
haemorrhage.  Of all the causes of portal  hypertension, a massive and 
disproportionately large spleen is seen most  commonly in NCPF.  Left 
upper quadrant pain due to perisplenitis and  splenic infarction is not 
uncommon.  NCPF also may have  odd  presentations, such a 
glomerulonephritis, hypoxemia or autonomic dysfunction37. 
Major presenting symptoms in Japanese patients with IPH were 
splenomegaly (88%), hepatomegaly (44%), gastrointestinal bleeding (35%) 
and ascites  (12%). 
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Natural history of NCPF/IPH   
  The survival curve for patients with NCPF/IPH is somewhat between that 
for those with cirrhosis  and for a healthy population of comparable age39. Good 
prognostic features in patients with NCPF, a 2- and 5-year survival of nearly 100% 
after  successful eradication of esophagogastric varices, have been described 29. 
Hillaire et al 8 reported death in 4 out of 28 patients with IPH owing to terminal 
liver failure. Development of PVT in a patient with IPH may be a significant factor 
for poor prognosis, and ascites may indicate a deterioration of the condition in 
patients with IPH. Furthermore, PVT and ascites may be mutually related in this 
disease.  
Histopathology of NCPF/IPH 
Autopsy liver- Gross examination may reveal a normal, enlarged, or 
even shrunken liver. Subcapsular septation can be noted, while deeper 
parenchyma shows normal architecture.Sclerosis of large to small 
intrahepatic portal vein branches and approximation of portal tracts to 
surface has been documented 39.Histological features noted in autopsies 
include increased portal collagenous connective tissue and sclerosis and  
obliteration of small branches of portal veins in most cases4. This 
histological hallmark of NCPF was termed obliterative portal venopathy by 
Nayak and Ramalingaswami. Intimal fibrosis and elastosis is also common, 
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leading to subendothelial thickening of the wall of large- and medium-sized 
portal vein branches even compromising the lumen. Veins may be thickened 
to the extent that they resemble an artery. Furthermore, aberrant vasculatures 
characterized by thin-walled vessels mainly located adjacent to the portal 
tracts and at times in the hepatic lobules have been described. Mild 
inflammation is seen in a few cases. Incomplete portal pseudolobule and 
scattered regenerative nodules may be noted in a few cases.  
Needle biopsies-Biopsy material may show only mild and subtle 
changes from normal. These changes include inconspicuous portal tracts and 
obliterated veins, or fibrous expansion of portal tracts4. Alternatively there 
may be dilatation of vessels in or near portal tracts, with vessel-like 
dilatation of sinusoids. Ludwig et al. studied the changes in 25 liver biopsies. 
Changes in the portal tract included capillary dilatation, phlebosclerosis, and 
fibroelastosis of the stroma. Portal vein dilatation with herniation into the 
surrounding hepatic parenchyma was also noted35. 
Wedge biopsies- Wedge biopsies show changes similar to autopsy 
material, but changes in medium and large portal vein branches may not be 
seen if not sampled4. A deep-core wedge biopsy (not broad-based wedge) 
along with a needle biopsy should be taken, as they would complement each 
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other in the information provided. This material may be valuable in looking 
for clues to the etiopathogenesis of NCPF 
Laboratory features: 
Patients usually have preserved hepatic function.The tests of liver 
function are normal.  Pancytopenia is found in the majority of patients.  
Anemia may be microcytic, hypochromic (due to GI blood loss) or 
normocytic, normochromic (due to hypersplenism)4.  Leucopenia 
(<4000/cumm) and thrombocytopenia (platelets <50,000/cumm) may also be 
present due to hypersplenism.  Whether the leucopenia in NCPF increases 
susceptibility to infections and whether splenectomy is required in such  
cases remain debatable.  The bone marrow is hypercellular.  Coagulation and 
platelet function anomalies also have been observed.  Mild compensated 
disseminated intravascular coagulation secondary to endotoxemia or 
portosystemic collaterals has been reported in a fair proportion of these 
patients41. 
Imaging: 
Ultrasonography shows a dilated and patent splenoportal axis with 
significantly thickened walls of the portal vein and to main branches.  
Doppler studies are helpful in identifying an occasional patient who has a 
thrombus in the intrahepatic branch  of the portal vein42. 
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Endoscopy:  
Esophagogastric varices are seen in 85-95% of patients who have 
NCPF.   Furthermore, patients with NCIPH have large varices more often 
(90%) compared with cirrhotic patients (79%).Anorectal varices also are 
more common (90% versus 56%) and are bigger in size53.Gastric varices are 
more common in NCPF. 
Hemodynamics in NCPF/IPH:  
The portal vein pressures are elevated markedly in patients who have 
NCPF. Two pathoanatomic sites of obstruction have been identified. A  
pressure gradient exists between the spleen and the liver (intrasplenic 
pressure – intrahepatic pressure [IHP]) and another exists between the IHP 
and the wedged hepatic  venous pressure(WHVP) (IHP – WHVP).  
Generally, the WHVP is normal or only slightly elevated in NCPF. Variceal 
pressure also has been studied in these patients and is comparable to that in 
cirrhotic portal  hypertension44.Intravariceal pressure closely reflects portal 
pressure in  patients who have NCPF and is the investigation of choice for  
measurement of portal pressure. 
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Management: 
For acute bleeding varices, variceal band ligation and endoscopic  
sclerotherapy are  equally efficacious (approximately 95% success in control  
of acute bleed)45.Prevention of re-bleeding with the use of non-selective β- 
blockers has been reported. B-blockers and endoscopic variceal ligation was  
found to be equally efficacious for primary prophylaxis in non-cirrhotic  
patients46. Gastric varices, can be managed with cyanoacrylate glue injection  
and rarely require  surgical intervention.  Interventional radiological  
procedures have been reported to be  effective in patients with IPH.  These  
include splenic embolisation, percutaneous  transhepatic obliteration and a  
transjugular intrahepatic porbosystemic shunt (TIPSS) procedure.   
The role of surgery is limited in variceal bleed because it is required 
in less than 5% of  cases of NCPF that fail to respond to endoscopic 
therapy47.  Selective shunts like distal splenorenal shunts are preferred 
because they have a lower  incidence of post shunt encephalopathy. 
However if massive splenomegaly is present, the proximal shunt with 
splenectomy is a good choice.  Surgery also is indicated for patients  who 
have symptomatic hypersplenism, for patients who hail from distant areas, 
or for  those who desire one-time treatment. The surgical mortality after 
emergency shunts is about 10%.  Shunt occlusion, overt chronic porto 
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systemic encephalopathy and re-bleeding after elective shunt surgery are 
seen in about 10% patients45.  After successful eradication of esophago-
gastric varices, 100% 2 and 5 year survival is observed in these, patients48. 
The long term outcome of shunt surgery also is favorable and 88% 5 year 
survival has been reported.  
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METHODOLOGY 
STUDY DESIGN: 
CASE CONTROL STUDY-  
Folate metabolism was prospectively analysed in patients with Idiopathic 
noncirrhotic intrahepatic  portal hypertension(NCIPH) and compared with age and 
geography matched healthy controls and disease controls 
Period of recruitment was over a period of 2 years (JAN 2007 to JAN 
2009).  Blood samples for evaluation of folate metabolism including 
MTHFR gene mutation  analysis were collected in the Liver clinic OPD or  
in the WARD.   
The study was approved by Research and Ethics committees (IRB) of 
the Christian Medical College, Vellore.  
Inclusion Criteria 
1. Subjects with NCIPH : 
a. Age 18 – 70 years 
b. Evidence of portal hypertension – esophageal varices, 
hypersplenism, ascites 
c. Doppler ultrasound – showing patent portal and hepatic veins  
d. Liver biopsy showing no cirrhosis 
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e. Exclusion of conditions causing cirrhosis, such as chronic viral   
hepatitis, alcoholic liver disease, non-alcoholic steatohepatitis 
(NASH), obesity, hemochromatosis, autoimmune hepatitis, 
Wilson’s disease, chronic vitamin A intake, professional 
exposure to copper sulphate, vinylchloride, past angiography 
with thorium sulphate, exposure to arsenic salt/herbal medicine.  
2.  Disease Controls: 
a. Age 18-70 years 
b. Cirrhosis of known  aetiology – HBV, HCV 
3.  Healthy Controls – Age, Sex and Geography matched. 
Variables: The following variables were measured: 
 Serum vitamin B12, 
 Serum folate   
 Fasting serum homocysteine  
 MTHFR gene mutation analysis 
METHODS:  
Serum Vitamin B12 – was measured   by competitive 
chemiluminescent enzyme immunoassay involving an automated alkaline  
denaturation  procedure  using IMMULITE 2000 analyzer(DPC California). 
Serum levels less than 200 pg/ml were considered to be low ,but for the 
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purpose of the study we took levels less than 250 pg/ml to be low. This is 
because almost all the patients attending the liver clinic had been to various 
hospitals before and would have received vitamin supplements .   
  Serum Folate – was measured by competitive immunoassay using 
IMMULITE 2000 analyzer and levels less than 3 ng/ml were considered to 
be low.  
Fasting serum homocysteine levels – were measured by HPLC (High 
performance liquid chromatography) .Typically, a level less than 13 micro 
mol/L is considered normal.A level between 13 and 60 u mol/L is 
considered moderately elevated.  A value greater than 60-100 u mol/L is  
severely elevated19  
Analysis of MTHFR gene mutation – PCR(Polymerase chain 
reaction) / RFLP(Restriction fragment length polymorphism) 
GENETIC ANALYSIS 
DNA isolation: 
Blood samples were collected in EDTA coated vacutainer tubes 
Greiner bio-one) from individuals with NCIPH, healthy controls and patients 
of  HBV/HCV related cirrhosis after getting informed written consent. DNA 
isolation was carried out by salting-out method . This method was chosen 
because this method replaced corrosive organic solvents used in the 
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conventional method with saturated salt solution and hence non hazardous to 
the user and the environment. 
Blood samples were centrifuged at 4000 rpm for 15 min at 4 °C to 
collect the WBC rich buffy coat. This step was used to reduce the usage of 
RBC lysis buffer volume and also to improve the DNA yield. Three layers 
were visible after centrifugation and they were: the top yellow layer 
containing the plasma, the middle white layer was the buffy coat and the 
bottom red was the erythrocytes. Plasma was carefully removed and 
discarded in a disposal glass beaker and then the buffy coat was collected 
along with little of erythrocytes in a fresh tube. Ten volumes of RBC lysis 
buffer was added and incubated at room temperature for 10 min. The lysis 
was checked by looking at the transparency of the solution. Then the tube 
was centrifuged at 4000 rpm for 10 min at 4°C. The supernatant was 
discarded in a disposal glass beaker leaving behind the white pellet of WBC 
in the tube. The wash was repeated until a clear white pellet was obtained. 
To the pellet 4.5 ml of WBC lysis buffer was added and the pellet was 
disturbed to get homogeneous solution. 250 µl of 10% SDS and 100 µl of 
Proteinase K was added and mixed well and incubated at 37° C for 
overnight or at 55°C for two hours.  The lysis was checked at the end of the 
incubation period and in the case of incomplete lysis, 50 µl of Proteinase K 
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was added and the digestion period was extended. After the digestion, 1.5 ml 
of saturated NaCl solution was added and mixed well till the solution turned 
milky white. This was then centrifuged at 4000 rpm for 15 min at 4°C and 
the supernatant was collected in a fresh 15 ml centrifugal tube. Two volumes 
of absolute ethanol was added to the supernatant and mixed gently, a white 
thread like structure appeared and reached the top of the solution. The thread 
like structure was collected in a fresh eppendorf tube containing 1ml of 70 % 
ethanol, using a sterile pipet tip. The tube was tapped to remove the excess 
salt adhering to the precipitate, and then the precipitate was transferred into 
another sterile eppendorf tube and allowed for air dying. When the 
precipitate turned transparent, 200-300 µl of TE buffer was added and stored 
in -20°C deep freezer until the polymorphic analysis was carried out.  
MTHFR POLYMORPHIC ANALYSIS 
The two MTHFR gene polymorphisms, C677T and A1298C were 
analyzed by PCR-restriction fragment length polymorphism (PCR-RFLP) 
method . The primer sequences were: 5'-TGA AGG AGA AGG TGT CTG 
CGG  GA-3' and 5'-AGG ACG GTG CGG TGA GAG TG-3' for C677T and 
5'-CTT  CTA CCT GAA GAG CAA GTC-3' and 5'-CAT GTC CAC AGC 
ATG GAG-3'  for A1298C. 
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The PCR reactions were carried out in 20 µl volume and each reaction 
mix contained 1x buffer with 1.5 mM MgCl2, 200 µM of dNTPs 
(Finnzymes, Finland), 250 nM of forward and reverse primers (Sigma 
genosys, India), 1 unit of JumpStart Taq DNA polymerase (Sigma, USA). 
The PCR condition was optimized by performing gradient PCR with a 
temperature range of 55-65°C. The thermal cycling protocol for C677T and 
A1298C polymorphisms comprised of initial denaturation at 95°C for 1 min, 
cycle denaturation at 94°C for 30 sec, annealing temperature at 63°C for 30 
sec, extension at 72°C for 30 sec, and the cycle was repeated for 39 more 
times, final extension at 72°C for 8 min. The PCR  products were checked 
for amplification by resolving on 2% agarose gel electrophoresis and 
checked with UV transilluminator (Vilbert Lourmat, France).  
The PCR products sizes were 198 and 256 bp respectively for C677T 
and A1298C.Then the amplified samples were digested with 1 unit of 
restriction enzymes, HinfI and MboII (New England Biolabs) respectively 
for C677T and A1298C analysis at 37°C for 16 hours. The digested PCR 
products were resolved on 2% agarose gel electrophoresis and the gel 
patterns were documented using a gel documentation system (Vilbert 
Lourmat, France). In the C677T analysis, the digestion pattern of two bands 
of size 175 and 23resulted from complete digestion corresponds to mutant 
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TT genotype and three bands with 198, 175 and 23 bp corresponds to CT 
genotype whereas the undigested marked the presence of CC genotype. The 
complete digestion resulting in four bands of 176, 30, 22 and 28 bp 
represents wild AA genotype; partial digestion resulting in five bands of 
204, 176, 30, 22 and 28 bp corresponds to AC genotype whereas digestion 
yielding 204, 30  and 22 bp showed the presence of CC genotype in A1298C 
analysis. 
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Polymorphism analysis of the methylenetetrahydrofolate reductase gene (MTHFR) 
amplicons by agarose gel electrophoresis after restriction endonuclease digestion 
(RFLP). – ¨677 position was digested by HinfI revealing the genotypes CC(wild 
type)(198bp band), CT and TT (175bp band). B) – 1298 position was digested by MboII 
and presented the genotypes AA (wild type, 100bp band), AC and CC (72bp band) 
C677T POLYMORPHISM 
PCR AMPLIFICATION 
 
 
 
RESTRICTION FRAGMENT LENGTH POLYMORPHISM 
 
 
 
A1298C POLYMORPHISM 
PCR AMPLIFICATION 
 
 
 
RESTRICTION FRAGMENT LENGTH POLYMORPHISM 
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CONSENT: 
Informed written consent (Annexure 1) was taken for blood collection 
and DNA analysis prior to the study. Peripheral blood sample (10ml) was 
collected from the antecubital vein using  EDTA coated vacutainer tubes. 
This blood was stored at -20 degree Celsius. Genetic studies were performed 
at Wellcome  Research Laboratory ,CMC,Vellore . 
STATISTICAL ANALYSIS: 
Data was analysed by statistical software SPSS (Statistical Package 
for Social Sciences, release 11.0, standard version; SPSS Inc). 
This was a prospective case control study and data of the 
cases(NCIPH) was reported as median with ranges for continuous variables 
and as frequencies and percentages for categorical variables. 
Fisher exact test was used to assess for significance of genetic 
mutations in cases and controls.  A p value of less than or equal to 0.05 was 
considered statistically significant.  Spearman’s correlation was used to 
calculate the correlation coefficient  between vit B12  and  serum 
homocysteine, MELD score and vit B12  in NCIPH patients.  Simlarly 
correlation coefficient  was calculated between MELD and vit B12 in 
cirrhotic patients. 
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RESULTS 
Age Distribution:  
The median age of presentation in NCIPH patients was 32.5 years, the 
youngest being 15 years and eldest being 62 years. 
Sex distribution: 
31 (68%) of the patients were male and the rest 15(32%) were female, 
the male to female ratio being 2.13:1 
Geographic distribution: 
20 patients (43%) were from Eastern India 
16 patients(35%) were from South India 
10 patients (22%) were from Northern India 
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TABLE 1 -BASELINE CHARECTERISTICS OF NCIPH PATIENTS (N=46) 
VARIABLE   MEDIAN (RANGE) 
AGE (yrs) 32.5(15-62) 
SEX*                                                              M-68% 
Hb(gm%) 9.3(3.8-15.1) 
TC(/cmm) 3000(900-11600) 
PLC(/cmm)                                                     54000(19000-490000) 
T.BILIRUBIN(gm/dl)    1.35(0.5-6.1) 
T.PROTEIN(gm/dl)                                        7.5(5.2-9.0) 
ALBUMIN(gm/dl)                                          3.8(2.4-4.6) 
AST(U/L)                                                        42.5(18-77) 
ALT(U/L)                                                        28.5(12-96) 
ALKALINE PHOSPHATASE 100.5(35-72) 
MELD                                                             9(6-16) 
HVPG(mmHg)                                               7(2-18)      
VIT B12(pg/ml)                                              323(50-1976) 
FOLATE(ng/ml   )                                          14.3(1-22.6) 
SERUM 
HOMOCYSTEINE(micromoles/L)#              
15.2(4.5-29.5) 
#-measured in 19  NCIPH patients 
* Percentage of total NCIPH patients 
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Clinical presentation and lab parameters of NCIPH patients: 
Anemia / lump in the abdomen was the first presentation in 50%(23) 
of the patients of which 17 patients first visited haematology and were 
referred to  liver clinic for the evaluation of suspected portal hypertension 
after the haematological evaluation for anemia was found to be negative. 
The next common presentation was variceal bleed ,seen in 43%(20) of the 
patients followed by ascites which was first presentation in 7%(3) of the 
patients(FIG 1) . 
Hypersplenism as defined as cytopenia involving one or more cell 
lines in the setting of portal hypertension was present in 36 patients(78%). 
FIG 1 
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Liver function tests showed mild unconjugated hyper bilirubinemia in 
22 patients(48%) and Serum albumin was <3 in 10(7%)  patients. 
Prothrombin time (PT) was near normal in all the patients with NCIPH. 
Median MELD score at presentation  was 9 (Range 6-16). 
Hepatic vein pressure studies: 
Of the 46 NCIPH patients 39 underwent  transjugular liver biopsies 
and HVPG  was measure in 26 patients. 
Of the  26 NCIPH patients who underwent pressure studies  
o HVPG<5mm Hg was seen in 8 patients 
o HVPG(5-10mm Hg) was seen in 11 patients 
o HVPG>10mm Hg was seen in 7 patients. 
Results of evaluation of folate metabolism: 
NCIPH patients(n-46): 
VITAMIN B12-  Median levels of serum vitamin B12 levels was 323 
pg/ml (Range 50-1976pg/ml) and levels <250 pg/ml was seen in 30% (14) of 
the patients as depicted in FIG 4. 
SERUM FOLATE –Median serum folate level was 14.3  ng/ml 
(Range 1-22.6 ng/ml) and low folate levels(<3ng/ml) was seen in only one 
patient. 
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FASTING SERUM HOMOCYSTEINE-Fasting serum homocysteine 
could  be measured in 19 NCIPH patients and the median value was 15.2 
micromoles/l (Range 4.5-29.5 mic mol/l). Levels greater than 13 
micromoles/l is considered as hyperhomocysteinemia 19  which was seen in 
12 patients. 
Healthy controls(n-109): 
Of the 109 age and geography matched healthy controls included in the 
study, serum vitamin B12 and folate levels could be measured in 72 patients. 
VIT B12-Median levels of serum vitamin B12 levels in matched healthy 
controls was 309.45pg/ml(Range  82.48-1027 pg/ml) and levels <250 pg/ml 
was seen in 36%(26) as depicted in FIG 5 and Table 2  . 
SERUM FOLATE-Median serum folate level was   7.32ng/ml (Range 
2-15.61  ng/ml) and low folate levels (<3ng/ml) was seen in two  patients. 
Cirrhosis (HBV/HCV)(n-42)- 
VITAMIN B12-Median levels of serum vitamin B12 levels in 
matched cirrhosis patients was 1022.4 pg/ml(Range 171-2000 pg/ml) and 
levels <250 pg/ml was seen in 5% (2) of the patients as depicted in FIG 6 
and Table 2 . 
SERUM FOLATE-Median serum folate level was  9.58 ng/ml(Range 3.8-24 
ng/ml) and low folate was found in none of the cirrhosis patients (Table 2). 
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The prevalence of vitamin B12 deficiency was significantly higher in 
NCIPH patients and healthy controls when compared to HBV/HCV cirrhosis 
(by Chi square test, P value being 0.002). There was no significant 
difference in the prevalence of folate deficiency in the three groups. 
TABLE 2 
SERUM VITAMIN B12 LEVELS >250pg/ml <250pg/ml(D
EFICIENT) 
NCIPH(N-46) 32 14 
HEALTHY CONTROLS(N-72) 36 26 
HBV/HCV CIRRHOSIS(N-42) 40 2 
 
TABLE 3 
SERUM FOLATE LEVELS >3ng/ml <3ng/ml(DEFI
CIENT) 
NCIPH(N-46) 45 1 
HEALTHY CONTROLS(N-72) 70 2 
HBV/HCV CIRRHOSIS(N-42) 42 Nil 
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FIG 2-DISTRIBUTION OF VITAMIN B12 LEVELS IN THE THREE  GROUPS-
DEPICTION IN THE SCATTER PLOT 
 
 
Vitamin B12 deficiency etiological workup 
Complete etiological workup for vitamin B12 deficiency was not done in the 
present study. 
Out of 13 NCIPH patients with vitamin B12 deficiency, 2 patients are pure 
vegetarians, 5 patients underwent duodenal biopsy of which 1 had villous 
atrophy, 1 had chronic duodenitis and 3 were normal. 
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The one with villous atrophy had low urine D xylose and 72 HR stool fat 
was high 
IF (Intrinsic factor) antibody screen was done in 3 and all were negative for 
the antibody. 
FIG 3-DISTRIBUTION OF FOLATE  LEVELS IN THE THREE  GROUPS-
DEPICTION IN THE SCATTER PLOT 
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MCV and Iron deficiency in NCIPH patients 
TABLE 4 
NCIPH PATIENTS MCV(fl) 
 
MEDIAN (RANGE) 
IRON DEFICIENCY* 
(NUMBER OF 
PATIENTS) 
VIT B12<250pg/ml# 
 
84.2(54.2-100.1) 7 
VIT B12>250pg/ml§ 
 
82.35(60-112) 13 
*Serum Ferritin<20microgram/l in males and < 5 mic g/l in females and / or Transferrin 
saturation<18% 
# 11 out of the total 13 NCIPH patients with vitamin B12 deficiency had iron indices 
tested  
§ 21 out of the 33 NCIPH patients with normal vitamin B12 had iron indices tested 
 
Of the 31 patients with NCIPH in whom iron indices were tested, 
evidence of iron deficiency was seen in 20 patients of which 7 had 
concomitant iron and vitamin B12 deficiency.  
In vitamin B12 deficient NCIPH group, MCV was normal (70-90 fl) 
in 6, low(<70 fl) in 3 and high(>90fl) in 4 patients. Concomitant iron 
deficiency was seen in 7 patients of which 2 had elevated MCV, 2 had low 
MCV and 3 had normal MCV. 
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Excluding the one outlier 
depicted in the graph(Fig 7) there was 
no significant correlation between 
serum VIT B12  and fasting serum 
homocysteine in NCIPH patients (by 
Spearman’s correlation)      Fig 7 
Correlation coefficient- 0.453    P value-0.052 
CORRELATION BETWEEN SERUM VITAMIN B12 AND MELD IN NCIPH 
PATIENTS-            
                                        Fig 8 
Correlation coefficient: 0.038                      P value: 0.851    
 
0
20
40
60
80
100
120
0 200 400 600 800 1000 1200
B12 level (pg/ml)
H
om
oc
ys
te
in
e 
le
ve
l 
(m
ic
ro
m
ol
es
/L
)
There was no significant 
correlation (Fig 8) between serum 
VITAMIN B12 and MELD in 
NCIPH patients (Spearman’s 
correlation)     
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Significant positive 
correlation(Fig 9) was seen between 
serum VITAMIN B12  and MELD  in 
HBV/HCV cirrhosis. 
 
            Fig 9 
Correlation coefficient :0.55                          P value:0.00 
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ANALYSIS OF MTHFR GENE POLYMORPHISM: 
The two MTHFR gene polymorphisms C677T and A1298C were 
analysed by PCR- RFLP in three groups namely the NCIPH cases, healthy 
controls and cirrhotic(HBV/HCV) patients. 
Healthy controls and  Healthy controls along with Cirrhosis group 
followed the Hardy Weinberg equilibrium.  (For which polymorphism?) 
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PREVALENCE OF MUTANT ALLELES FOR C677T  POLYMORPHISM- 
The prevalence of mutant alleles (T) in NCIPH group was 4%, healthy 
controls was 15% and in cirrhosis group was 13%. 
Thus, the mutant alleles were significantly higher in Healthy controls 
when compared to NCIPH group with a P value of 0.02 (Fisher’s exact test), 
Relative risk of 0.80(95% CI 0.71-0.91) and Odds ratio of 0.25(95%CI 0.07-
0.84) were noted, indicating that the mutation had protective association 
against NCIPH with an effect of approximately 20%. 
PREVALENCE OF C677T ALLELES IN HEALTHY CONTROLS AND NCIPH 
ALLELES H.CONTROLS NCIPH TOTAL 
C677T 
     C 
     T 
 
185 
33 
 
67 
3 
 
252 
36 
TOTAL 218 70 288 
                                                                                                       P VALUE:0.02 
PREVALENCE OF C677T ALLELES IN NCIPH AND HBV/HCV CIRRHOSIS 
ALLELES NCIPH HBV/HCV CIRRHOSIS TOTAL 
C677T 
     C 
     T 
 
67 
3 
 
49 
7 
 
116 
10 
TOTAL 70 56 126 
                                                                                                         P VALUE:0.1 
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PREVALENCE OF MUTANT GENOTYPE FOR C677T  POLYMORPHISM- 
The prevalence of mutant genotype(heterozygous CT/homozygous 
TT) in NCIPH was 9%, healthy controls was 28% and Cirrhosis patients was 
21% (sample size in the cirrhosis group was 28). 
The mutant genotype was significantly higher in healthy controls 
when compared to NCIPH group with a P value of 0.02 (Fisher’s exact test), 
Relative risk of 0.78(95% CI 0.67-0.92) and Odds ratio of 0.25(95%CI 0.07-
0.86). 
PREVALENCE OF C677T MUTANT GENOTYPES  IN HEALTHY CONTROLS AND 
NCIPH 
GENOTYPE H.CONTROLS NCIPH TOTAL 
WILD 79 32 111 
MUTANT 30 3 33 
TOTAL 109 35 144 
                                                                                                          P  VALUE:0.02 
PREVALENCE OF C677T MUTANT GENOTYPES  IN NCIPH AND HBV/HCV 
CIRRHOSIS 
GENOTYPE NCIPH HBV/HCV CIRRHOSIS TOTAL 
WILD 32 22 54 
MUTANT 3 6 9 
TOTAL 35 28 63 
                                                                                                          P VALUE:0.17 
 
 
 
 49
PREVALENCE OF MUTANT ALLELES FOR A1298C  POLYMORPHISM- 
The prevalence of mutant alleles(C) in NCIPH group was 
34%,healthy controls was 40% and in cirrhosis group was 38%. 
There was no statistically significant difference of the prevalence of  
mutant alleles between NCIPH group and healthy controls ; NCIPH group 
and cirrhosis  group (Fisher exact test).  
PREVALENCE OF A1298C ALLELES IN HEALTHY CONTROLS AND NCIPH 
ALLELES N.CONTROLS NCIPH TOTAL 
A1298C 
           A 
           C 
 
129 
85 
 
46 
24 
 
175 
109 
TOTAL 214 70 284 
                                                                                                          P VALUE-0.47 
PREVALENCE OF A1298C  ALLELES IN NCIPH AND HBV/HCV CIRRHOSIS 
 
ALLELES NCIPH HBV/HCV CIRRHOSIS TOTAL 
A1298C 
        A 
        C 
 
46 
24 
 
37 
19 
 
83 
43 
TOTAL 70 56 126 
                                                                                                             P VALUE-1 
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PREVALENCE OF MUTANT GENOTYPES FOR A1298C POLYMORPHISM:- 
The prevalence of mutant genotypes(Heterozygous AC/Homozygous 
CC) in NCIPH group was 57%, healthy controls was 70% and in cirrhosis 
group was 46%. 
There was no statistically significant difference of the prevalence of  
mutant genotypes between NCIPH group and healthy controls ; NCIPH 
group and cirrhosis  group(Fisher exact test). 
PREVALENCE OF A1298C  MUTANT GENOTYPES  IN HEALTHY CONTROLS AND 
NCIPH 
GENOTYPE H.CONTROLS NCIPH TOTAL 
WILD 32 15 47 
MUTANT 75 20 95 
TOTAL 107 35 142 
                                                                                                        P VALUE-0.21  
PREVALENCE OF A1298C MUTANT GENOTYPES  IN NCIPH AND HBV/HCV 
CIRRHOSIS 
GENOTYPE NCIPH HBV/HCV CIRRHOSIS TOTAL 
WILD 15 15 30 
MUTANT 20 13 33 
TOTAL 35 28 63 
                                                                                                      P VALUE-0.45 
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DISCUSSION 
The current study is a prospective evaluation of folate metabolism 
with particular reference to MTHFR gene mutation (C677T nad A1298C 
polymorphisms) in Idiopathic Non cirrhotic Intrahepatic Portal 
Hypertension(NCIPH). 
 
DEMOGRAPHY: 
The median age at presentation in NCIPH was 32.6 yrs(Range 15- 
62).  Several studies in the past described mean age ranging from 25-35 
years29.  Koshy described a double peak  in age  incidence one at 21-25 yrs 
and the other at 36-40 yrs49. 
The male to female ratio was 2.13:1 as was seen in series from 
different parts of India(2:1 to 4:1)12,16.Majority of patients were from North 
and Northeastern India.. 
CLINICAL AND LAB FEATURES IN IDIOPATHIC NCIPH: 
In our study, the most common first clinical presentation  was anemia 
with lump in the abdomen which  was seen in 23 patients(50%) followed by 
variceal bleed seen in 43%. Ascites was the presentation in 3 patients .  In a 
data based experience from North India, variceal bleed was seen in 84%, 
LUQ mass in 13.5%and ascites in 10% in NCPF29.In another retrospective 
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study from North India lump in the abdomen was the commonest first 
presentation (68.9%) followed by gastrointestinal bleeding5.  
Of the patients presenting with anemia and lump(splenomegaly),17 
went through  haematology OPD and after exclusion of the primary 
haematologic disorder were  referred to Liver clinic.  
78% of the patients had hypersplenism defined as cytopenia involving 
one or more cell lines in the setting of portal hypertension which is similar to 
that seen in other studies5. 
LFT showed mild unconjugated hyperbilirubinemia in 22 patients 
(48%) and serum albumin < 3 gm% in 10 patients though Prothrombin time 
(PT) was near normal in all. The parenchymal damage manifest by increased  
aminotransferase levels is very minimal in NCPF. Results of conventional 
tests of liver function are normal or near normal5. Progression to liver failure 
is increasingly  documented in NCIPH in a subset  of patients 8, 50.  
Hillaire et al  in their study8 documented serum Bilirubin as high as 
5.4mg% at initial presentation.One of the patient in our study group 
underwent liver transplantation due to liver failure(in the form of recurrent 
hepatic encephalopathy) , the explant biopsies showed no evidence of 
Cirrhosis but had histological   features consistent with  NCIPH1.  
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HEPATIC VEIN PRESSURE STUDIES: 
Of the 46 NCIPH patients ,39 had Transjugular liver 
biopsies(indication being coagulopathy in the form of thrombocytopenia). 
HVPG was measured in 26 patients of which only 8 had HVPG <5mm Hg 
and rest had HVPG>5mm Hg. Elevated HVPG has  been reported in 
NCIPH, probably reflecting peri-sinusoidal resistance in addition to pre-
sinusoidal resistance to portal venous blood flow51. 
SIGNIFICANT DIFFERENCES IN VITAMIN B12 DEFICIENCY IN THE 
3 STUDY GROUPS: 
Serum vitamin B 12 levels < 250 pg/ml was seen in 30% of NCIPH  
group and 36% of age geography matched healthy controls.In  patients with 
HBV/HCV cirrhosis , vitamin B12 deficiency was seen in only 5% and 
median levels were 1022.4 pg/ml(Range 171-2000 pg/ml). 
WHY IS VITAMIN B12 DEFICIENCY SEEN IN 30% OF NCIPH 
PATIENTS? 
High levels of serum vitamin B12 in cirrhosis patients was probably 
due to  
hepatic parenchymal injury .Vitamin B12 is stored in the liver (estimated 1 
mg) and serum levels of vitamin B12 as assayed biologically are present in a 
variety of liver disorders particularly those accompanied by necrosis of liver 
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cells 52.The total serum content based on an average serum serum 
concentration of 300 ng/ml is of the same order as the total requirements 
estimated at about  1 mic g a day(This is the minimum dosage necessary to 
maintain a patient with pernicious anemia in haematologic remission) . 
NCIPH is a vascular disorder affecting  hepatic vasculature  at the 
presinusoidal level without hepatocyte injury and hence  the median vitamin 
B12 levels were significantly low when compared to Cirrhosis group and 
prevalence of vitamin B12 deficiency was  almost similar to that of  Healthy 
controls. 
HOMOCYSTEINE AND VIT B12 DEFICIENCY IN NCIPH: 
Fasting serum Homocysteine levels were elevated(>13micr mol/l) in 
12 out of the 19 NCIPH patients in whom it was tested.The median levels 
were 15.2 micromoles/l(Range 4.5-98 mic mol/l). There was no significant  
correlation between vitamin B12  and fasting serum Homocysteine levels.  
This may be because it is known fact that  relative deficiency of vitamin B12 
or folate cause elevation in serum homocysteine levels and most of the 
patients had been to various hospitals before coming to liver clinic and  had 
been on vitamin supplements.   
There was no significant difference between the serum folate levels in 
the three groups studied (NCIPH,Healthy controls and Cirrhosis group).   
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Prevalence of vitamin B12 deficiency in NCIPH in our study was  
nearly the same as seen in healthy controls .However significant difference 
was seen in HBV/HCV cirrhosis(majority had elevated vitamin B12 and 
only 2 patients had low levels). 
We thought of two explanations for this finding: 
1. Hepatocyte injury leading to the release of vitamin B12  into the 
circulation in HBV/HCV cirrhosis. 
2. Vitamin B12 deficiency is causally linked to NCIPH 
B12 DEFICIENCY CAUSALLY LINKED TO NCIPH: 
Our original hypothesis was that vitamin B12 being a gut derived 
vitamin, B12 deficiency would be maximal in the portal system.  This could 
be a prothrombotic factor driving microvascular occlusion  in portal vascular 
tree. 
Vitamin B12 deficiency was significantly higher compared  to 
HBV/HCV cirrhosis in our study.However ,the lack of significant difference 
in vit B12 deficiency amongst NCIPH patients and healthy controls appears 
not to fit our original hypothesis. 
One possibility is that vitamin B12 deficiency is so common in our 
population (about a third of healthy controls studied), this makes it difficult  
 
 
 
 56
 to show causal association between B12 deficiency and NCIPH.  We have 
not studied the causes of vitamin B12 deficiency in detail in our study. 
We postulate that silent gut disorders like tropical enteropathy may be  
involved.  In support of this, of the  5 patients who underwent duodenal  
biopsies ,one  had villous atrophy ,another reported as chronic duodenitis  
and the rest 3 had no significant lesion  . 
MTHFR C677T & A1298C POLYMORPHISMS:  
The two MTHFR gene polymorphisms C677T and A1298C were 
analysed in the three groups . 
The prevalence of mutant alleles(T) in NCIPH group was 4%,Healthy 
controls was 15% and the prevalence of mutant genotype(heterozygous 
CT/homozygous TT) in NCIPH was 9%,healthy controls was 28%. 
The mutant genotype and the mutant alleles were significantly higher 
in Healthy controls when compared to NCIPH group with a P value of 0.02 
(Fisher’s exact test). 
There was no statistically significant difference of the prevalence of  
mutant genotypes and mutant alleles for A1298C polymorphism between 
NCIPH group and healthy controls ; NCIPH group and cirrhosis  group. 
In a study published from Turkey28 where they analysed the inherited  
thrombophilic mutations and natural anticoagulant deficiency in patients  
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with idiopathic portal hypertension, MTHFR C677T and MTHFR A1298C 
frequencies of genetic polymorphisms were found to be significantly higher 
among patients than that of controls.But the sample size in this study was 
too small with 12 NCIPH and 13 controls.  
In contrast,  in our study we found MTHFR C677T  frequencies of 
genetic polymorphisms significantly higher in healthy controls than NCIPH 
group and there was no signicant difference for A1298 Cpolymorphism. 
Our data calls for further studies in larger number of patients. 
IS VITAMIN B12 DEFICIENCY OVERLOOKED IN NCIPH? 
We found that of the 14 patients with low vitamin B12  ,MCV was 
elevated in 4. 
It is possible that concomitant iron deficiency accounts for the 
normal/low MCV in the rest of the patients. 
Our study suggests that serum vitamin B12 levels should be routinely 
tested in Idiopathic Non cirrhotic Intrahepatic portal hypertension(NCIPH).  
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CONCLUSIONS 
1. The median serum level of vitamin B12 was significantly higher in 
patients with cirrhosis when compared with  Idiopathic Non cirrhotic 
Portal hypertension(NCIPH) and the prevalence of  vit B12 deficiency 
was 30%  in NCIPH compared to 36% in healthy controls(36%). 
Inference-This reflects the parenchymal damage in cirrhosis causing 
release of  vit B12 into the circulation and that there is no 
parenchymal(hepatocyte) injury  in NCIPH.  (Reference??) 
2. Among the NCIPH patients with low vitamin B12, MCV was low or 
normal in the majority with concomitant iron deficiency seen in the 
majority of the patients (7 out of 11 tested). 
3. Fasting serum Homocysteine was elevated  in 12 out the 19 patients of 
NCIPH in whom it was tested ,but there was no correlation with 
vitamin B12 deficiency. 
4. There was no difference in serum  folate levels in the NCIPH group 
when compared to Cirrhosis patients or Healthy controls. 
5. MTHFR C677T Polymorphism (both mutant  alleles and mutant 
genotypes)was more  prevalent  in healthy  controls than  NCIPH  
with a P value of 0.02 (Fisher’s exact test),Relative risk of 0.78(95%  
CI 0.67-0.92) and Odd’s ratio of 0.25(95%CI 0.07-0.86). 
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Inference: MTHFR C677T polymorphism being significantly more 
common in healthy population than NCIPH patients in our study 
suggests either a protective mutation or a chance association. This 
requires further study.   
6. There was no difference  in the prevalence of A1298C MTHFR poly 
morphism   between NCIPH patients and healthy controls.  
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PROFORMA 
Serial Number        
Name 
Age 
Sex 
Hosp.Number 
Address 
First clinical presentation 
HISTORY OF 
 Gastrointestinal bleed 
Abdominal distension 
Altered sensorium 
Mucosal bleed (Gum bleed / Epitaxis etc) 
Personal and Dietary history 
CLINICAL EXAMINATION 
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LAB INVESTIGATION 
 CBC 
 LFT 
 PT 
 Etiological workup for known causes of liver disease 
 MELD score at presentation 
 
IMAGING 
 Ultrasound abdomen / Colour Doppler 
GASTROSCOPY 
LIVER BIOPSY 
HVPG (Hepatic venous pressure gradient) 
SERUM VITAMIN B12 / SERUM FOLATE 
FASTING SERUM HOMOCYSTEINE 
MTHFR GENE MUTATION ANALYSIS 
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CONSENT FORM 
 
I understand that Dr. K.MADHU is doing a study to evaluate the 
causative factors in patients with non-cirrhotic portal hypertension and 
cirrhosis of unknown cause.  The studies involve blood tests to detect how 
my body utilizes a vitamin that is necessary for good health of the blood 
vessels.  The results of the test done in connection with the study may 
directly benefit me.  They are likely to indirectly benefit other patients with 
the disease. 
I accept to undergo the work up required to be done during the study 
and provide the blood samples for estimation of serum vitamin B12, Folate 
and homocystein levels and MTHFR gene mutation. 
I understand that my withdrawal from the study, at any time will not 
affect the treatment being given. 
 
Study Title: 
Study Number: 
Subject’s Initials: _________ Subject’s Name: ________ 
Date of Birth / Age:_______ 
Please initial box  
(Subject) 
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(i)   I  confirm  that  I  have  read  and  understood  the  information  sheet  dated 
_________ for the above study and have had the opportunity to ask questions. [ 
] 
(ii)   I understand that my participation in the study is voluntary and that I am 
free  to withdraw  at  any  time, without  giving  any  reason, without my medical 
care or legal rights being affected. [ ] 
(iii)   I  understand  that  the  Sponsor  of  the  clinical  trial,  others  working  on  the 
Sponsor’s behalf,  the Ethics Committee and  the  regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw  from  the  trial.  I agree  to  this access. However,  I understand  that my 
identity  will  not  be  revealed  in  any  information  released  to  third  parties  or 
published. [ ] 
(iv)   I agree not  to  restrict  the use of any data or  results  that arise  from  this  study 
provided such a use is only for scientific purpose(s) [ ] 
(v)   I agree to take part in the above study. [ ] 
 
Signature  (or  Thumb  impression)  of  the  Subject/Legally  Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
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Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
 
